Clinical Trials Directory

Trials / Completed

CompletedNCT05410535

To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy

A Multi-center, Phase IV, Extension Study in PEGASUS-D Trial to Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
431 (actual)
Sponsor
Daewoong Pharmaceutical Co. LTD. · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Of those patients who participated in PEGASUS-D FAS clinical trial, patient must sign the informed consent form in order to participate in this extension study. The medical records of the patients will be reviewed throughout the study.

Detailed description

Of those patients who participated in PEGASUS-D FAS clinical trial, patient must sign the informed consent form in order to participate in this extension study. * Collection of retrospective cohort data 1)The medical records from the subject's gastrectomy surgery date to Visit1 will be collected through a questionnaire and by reviewing the medical records of the patient. * Collection of prospective cohort data 1. Based on visit 1, if the subjects whose date of gastrectomy surgery date is more than 3 years(36 months) and less than 5 years(60 months), the subject should visit the institution at the time of 5 years(60 months, visit2) after gastrectomy surgery to evaluate data requested at visit2. 2. The medical records will be accessed and collected from the subject's gastrectomy surgery date up to 5 years(60 months)

Conditions

Interventions

TypeNameDescription
DRUGPatients who continued UDCA 300mg medicationpatients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
OTHERPatients who discontinued UDCA 300mg prescriptionpatients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

Timeline

Start date
2021-09-15
Primary completion
2022-10-28
Completion
2022-10-28
First posted
2022-06-08
Last updated
2024-06-28

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05410535. Inclusion in this directory is not an endorsement.